For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the projected market size of the hereditary angioedema industry, and what is its expected CAGR?
The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the increasing prevalence of hereditary angioedema, increasing investment in research and development activities, increasing numbers of drug approvals, rising product approval, and rising disposable income.
The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to the growing prevalence of rare diseases, increasing medical expenditure, increasing support from non-profit organizations, increasing awareness of hereditary angioedema, and rising awareness about earlier diagnoses. Major trends in the forecast period include technological advancements, the development of novel therapies, the launch of new drugs, advanced diagnostic tools, and advancements in genetic testing.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp
What external factors are influencing the hereditary angioedema market’s growth momentum?
The growing prevalence of rare diseases is expected to propel the growth of the hereditary angioedema market going forward. Rare diseases, also known as orphan diseases, refer to medical conditions that affect a small percentage of the population. The increasing prevalence of rare diseases is due to multiple factors, such as progress in medical research, changes in population demographics, and environmental impacts. Hereditary angioedema (HAE) is a significant rare disease, highlighting the need for specialized treatments and awareness due to its life-threatening swelling episodes. Its rarity and genetic nature make early diagnosis and targeted therapies essential for effective management and improved patient outcomes. For instance, in June 2022, according to Rare Disease Advisor, a US-based online resource company that provides healthcare professionals, hereditary angioedema (HAE) affects approximately 1 in 50,000 individuals, with prevalence estimates ranging from 1 in 10,000 to 1 in 150,000. In the United States, HAE episodes result in approximately 15,000 to 30,000 emergency room visits each year. Therefore, the growing prevalence of rare diseases is driving the growth of the hereditary angioedema market.
What are the major market segments driving the growth of the hereditary angioedema industry?
The hereditary angioedema market covered in this report is segmented –
1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II
2) By Treatment Type: Prophylaxis, On-demand
3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes
4) By Route Of Administration: Subcutaneous, Intravenous, Oral
5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels, Reduced C1-Inhibitor Function
2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report
What are the key trends shaping the hereditary angioedema market in the forecast period?
Major companies operating in the hereditary angioedema market are developing innovative products, such as oral plasma kallikrein inhibitors, to provide more convenient and effective on-demand treatment options for patients. Oral plasma kallikrein inhibitors are drugs that block plasma kallikrein to prevent excessive bradykinin production, primarily used for treating hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the FDA has accepted its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the on-demand treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat provides a new treatment approach by targeting and inhibiting plasma kallikrein activity. The acceptance of the NDA represents a major milestone toward potential approval and commercialization.
Who are the key market players contributing to the growth of the hereditary angioedema industry?
Major companies operating in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc.
Which regions are leading the growth of the hereditary angioedema market globally?
North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Hereditary Angioedema Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22002
Need Customized Data On Hereditary Angioedema Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
